Kaia COPD, a digital therapeutic treating chronic obstructive pulmonary disease (COPD) has been preliminarily listed as a digital health application (DiGA) in the DiGA directory by the Federal Institute for Drugs and Medical Devices (BfArM). Kaia COPD is now eligible for reimbursement and can be prescribed by physicians in Germany.
- The startup Kaia Health was founded in 2016 and develops digital health applications treating a range of diseases such as back pain or COPD based on the core elements of multimodal therapy. Using artificial intelligence (AI), the applications adapt to the user’s individual pain intensity and capabilities. The efficacy of Kaia Health’ applications has been proven in multiple randomized controlled studies. Kaia Health employs about 100 people in Munich and New York.
- In Germany, about 3.4 million people are affected by COPD. With the preliminary listing, Kaia COPD now offers the first DiGA for the treatment of COPD patients. The therapy is based on customized training sessions, education and relaxation and breathing techniques. Using the camera of a smartphone or tablet, the integrated AI-powered motion coach can analyze movements in real time to correct the execution of exercises via voice or visual aids. The DiGA is certified as a class IIa medical device and costs €415 for 90 days.
- The digital therapeutic will be commercialized by Kaia Health in partnership with Chiesi GmbH, a company specialized in therapeutics for respiratory diseases. The Italian pharmaceutical company and the startup had announced their strategic partnership for the commercialization of the COPD application in Europe already in November 2020.
We congratulate Kaia Health as a member of our startup community and ecosystem on the successful admission to the DiGA directory and are looking forward to shaping the future of digital health.
Click here to read the entire press release.